000 | 01724 a2200505 4500 | ||
---|---|---|---|
005 | 20250514222347.0 | ||
264 | 0 | _c20050720 | |
008 | 200507s 0 0 eng d | ||
022 | _a0015-5500 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSobotkova, E | |
245 | 0 | 0 |
_aCharacteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells. _h[electronic resource] |
260 |
_bFolia biologica _c2005 |
||
300 |
_a12-8 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
650 | 0 | 4 | _aBenzamides |
650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
650 | 0 | 4 |
_aCell Line, Transformed _xmetabolism |
650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
650 | 0 | 4 | _aCell Shape |
650 | 0 | 4 |
_aCell Transformation, Neoplastic _xmetabolism |
650 | 0 | 4 |
_aCellular Senescence _xphysiology |
650 | 0 | 4 |
_aDown-Regulation _xphysiology |
650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xphysiology |
650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xgenetics |
650 | 0 | 4 |
_aHistocompatibility Antigens Class I _xmetabolism |
650 | 0 | 4 | _aImatinib Mesylate |
650 | 0 | 4 |
_aLeukemia _xdrug therapy |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred BALB C |
650 | 0 | 4 |
_aNeoplasm Invasiveness _xphysiopathology |
650 | 0 | 4 | _aNeoplasm Transplantation |
650 | 0 | 4 |
_aPiperazines _xpharmacology |
650 | 0 | 4 |
_aPyrimidines _xpharmacology |
700 | 1 | _aLudvíková, V | |
700 | 1 | _aPetrácková, M | |
700 | 1 | _aDusková, M | |
700 | 1 | _aSmetana, K | |
700 | 1 | _aJelínek, F | |
700 | 1 | _aMarinov, I | |
700 | 1 | _aVonka, V | |
773 | 0 |
_tFolia biologica _gvol. 51 _gno. 1 _gp. 12-8 |
|
999 |
_c15454934 _d15454934 |